- Home
- / Arcturus Therapeutics
Arcturus Therapeutics
Stock Price
$19.1
2024-10-29
Market Capitalization
$529.2 M
2024-10-29
Revenue
$82 M
FY, 2025
Arcturus Therapeutics Summary
Company Summary
- Overview
- Arcturus Therapeutics is a preclinical drug delivery and nucleic acid medicines company. It is focused on developing technologies to build RNA and DNA medicines. The company was formed as a result of a merger between Arcturus Therapeutics and Alcobra.
- Type
- Public
- Status
- Active
- Founded
- 2013
- HQ
- San Diego, CA, US | view all locations
- Website
- http://www.arcturusrx.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Padmanabh Chivukula, CSO & COO
Joseph E. Payne, President & CEO, Director of the Board
Andrew Sassine, Chief Financial Officer
LocationsView all
1 location detected
San Diego, CA HQ
United States
10628 Science Center Dr #250
Arcturus Therapeutics Financials
Summary Financials
- Revenue (Q1, 2026)
- $2.1M
- Net income (Q1, 2026)
- ($27.0M)
- Cash (Q1, 2026)
- $211.4M
- EBIT (Q1, 2026)
- ($28.9M)
- Enterprise value
- $337.5M